By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – VisionGate today announced it has raised $1.96 million in the first tranche of a financing round and forged two collaborations to evaluate its automated 3D cell imaging platform for the early detection of lung cancer.

The $1.96 million tranche is part of a targeted $3 million equity round and will be used for further clinical development of its technology. Participants included undisclosed new and existing investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.